| Hepatocyte Growth Factor (HGF) promotes the proliferation of various epithelial, endothelial, and mesenchymal cells in multiple organs. One clinically significant result of this activity is the apparent link between HGF concentration and fulminant hepatitis. Significant increases in serum HGF concentrations have been observed in fulminant hepatitis patients in comparison with those in other hepatitis. Further, HGF serum concentrations show abnormal elevation just before the onset of encephalopathy - which is well known to be associated with fulminant hepatitis - and decrease with recovery from it. The link between HGF and encephalopathy is strengthened by the observation that continued elevated levels of HGF after encephalopathy onset indicate a poor prognosis of recovery.
Unlike Prothrombin, another potential diagnostic marker for hepatitis which correlates with acute hepatitis, liver cirrhosis, or hepatocellular carcinoma, as well as fulminant hepatitis, HGF appears to be much more specific for fulminant hepatitis. Determination of HGF, therefore, has the potential to be an effective marker for the specific diagnosis of fulminant hepatitis in its early stages, and the potential prognosis of recovery.
B-Bridge HGF ELISA Kit is developed to measure the concentration of human HGF in culture supernantents or serum.
 |
|
|
| Fig.1 Human HGF Standard Curve |
|
Fig. 2 Mouse/Rat HGF Standard Curve
|
Standard Curve constructed by plotting concentration of the standard solution on the X axis and Net OD of the respective concentrations on the Y axis.
|
